Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Károly Zámolyi"'
Autor:
Károly Zámolyi
Publikováno v:
Hypertonia és Nephrologia. 24:261-267
A hypertonia a cardiovascularis betegségek – szívelégtelenség, coronariabetegség, stroke és krónikus veseelégtelenség – fő és leggyakoribb rizikófaktora. A hypertoniás szívbetegség egyik klinikai manifesztációja a különböző r
Autor:
Péter Andréka, János Tomcsányi, Károly Zámolyi, János Simon, András Vértes, Zoltán László, Péter Polgár, Sándor Bajkó, Róbert Gábor Kiss, Ferenc Juhasz, Béla Merkely, Imre Varjú, Péter Ofner, András Jánosi
Publikováno v:
Orvosi Hetilap. 152:1278-1283
Authors present the methodology and first data of Hungarian Myocardial Infarction Register Pilot Study started 1st of January, 2010. The aim of the study is to collect epidemiological data on myocardial infarction, to examine the natural history of t
Autor:
László Márk, László Romics, Mária Audikovszky, Károly Zámolyi, György Paragh, István Karádi, Gyula Pados
Publikováno v:
Hungarian Medical Journal. 2:593-602
Purpose: Improving the management of cardiovascular disease in Hungary represents an important clinical challenge. This article assesses the achievement of national consensus total cholesterol goals among Hungarian patients of physicians educated abo
Autor:
Béla Herceg, Béla Merkely, András Vértes, János Tomcsányi, Péter Polgár, András Katona, Elek Dinya, István Édes, Ferenc Juhász, Károly Zámolyi, Péter Ofner, Géza Lupkovics, Zoltán László, Imre Varjú, János Simon, Lajos Nagy, Ferenc Bajkó, Kálmán Csapó, András Jánosi, Róbert Gábor Kiss
Publikováno v:
Orvosi hetilap. 154(33)
Mortality data of patients with acute myocardial infarction are incomplete in Hungary.The aim of the authors was to analyse the data of 8582 myocardial infarction patients (4981 with ST-elevation myocardial infarction) registered in the Hungarian Myo
Autor:
András, Jánosi, Péter, Ofner, Béla, Merkely, Péter, Polgár, Péter, Andréka, Károly, Zámolyi, Róbert Gábor, Kiss, János, Tomcsányi, Zoltán, László, András, Vértes, Imre, Varjú, Ferenc, Juhász, János, Simon, Sándor, Bajkó
Publikováno v:
Orvosi hetilap. 152(32)
Authors present the methodology and first data of Hungarian Myocardial Infarction Register Pilot Study started 1st of January, 2010. The aim of the study is to collect epidemiological data on myocardial infarction, to examine the natural history of t
Publikováno v:
Clinical drug investigation. 27(9)
Background and objective: Cardiovascular disease is a leading cause of death in Eastern Europe. Few studies on cholesterol goal achievement have been conducted in Hungarian clinical settings. This study set out to evaluate lipid-modifying therapy pra
Autor:
Krisztián, Kárpáti, Valentin, Brodszky, Csaba, Farsang, György, Jermendy, Gyozo, Vándorfi, Károly, Zámolyi, László, Gulácsi
Publikováno v:
Orvosi hetilap. 147(40)
The third generation beta-blocker (carvedilol) is effective in reduction of hypertension, and of mortality and morbidity as a supplement to conventional drugs of heart failure therapies (diuretics, ACE inhibitors), based on randomized controlled tria
Autor:
Gyula, Pados, István, Karádi, György, Paragh, László, Halmy, György, Jermendy, Károly, Zámolyi, István, Kiss
Publikováno v:
Orvosi hetilap. 147(28)
The First Hungarian Therapeutic Consensus Conference took place on 3rd Nov. 2003 with the participation of 9 medical societies. Over the past 2 years the results of new major studies have been published and the American ATP III has also updated its g
Autor:
László, Voith, Tibor, Vecsey, László, Major, András, Zsoldos, Béla, Nagybaczoni, Péter, Andrássy, Károly, Zámolyi, Jańos, Tomcsańyi
Publikováno v:
Orvosi hetilap. 146(31)
At the two hospitals, first percutaneous coronary intervention was performed on 1031 patients (700 male and 331 female, average age 59.8 +/- 15.1 years) between July 2000 and June 2002. The indications were: stable effort angina 679 (65.8%), unstable
Publikováno v:
Orvosi hetilap. 146(4)
Recent European and Hungarian guidelines of cardiovascular prevention have clearly defined the target levels in lipid lowering therapy.To analyze the risk status of patients receiving long term lipid lowering therapy and the rate of achievement of ta